<- Go Home
InVivo Therapeutics Holdings Corp.
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Market Cap
$1.1M
Volume
101.9K
Cash and Equivalents
$8.6M
EBITDA
-$9.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$1.41
52 Week Low
$0.15
Dividend
N/A
Price / Book Value
0.13
Price / Earnings
-0.11
Price / Tangible Book Value
0.13
Enterprise Value
-$7.4M
Enterprise Value / EBITDA
0.79
Operating Income
-$9.9M
Return on Equity
98.11%
Return on Assets
-53.71
Cash and Short Term Investments
$8.6M
Debt
N/A
Equity
$8.9M
Revenue
N/A
Unlevered FCF
-$7.0M
Sector
Health Care Equipment and Supplies
Category
N/A